BG104432A - Терапевтично използване на хинолинови производни - Google Patents
Терапевтично използване на хинолинови производни Download PDFInfo
- Publication number
- BG104432A BG104432A BG104432A BG10443200A BG104432A BG 104432 A BG104432 A BG 104432A BG 104432 A BG104432 A BG 104432A BG 10443200 A BG10443200 A BG 10443200A BG 104432 A BG104432 A BG 104432A
- Authority
- BG
- Bulgaria
- Prior art keywords
- quinolinylmethyloxy
- compound
- alkyl
- tetrazole
- phenoxymethyl
- Prior art date
Links
- 0 *CNC(Cc1cccc(COC(C2)C=CC=C2OCC2N=C(C=CC=C3)C3=CC2)c1)=N Chemical compound *CNC(Cc1cccc(COC(C2)C=CC=C2OCC2N=C(C=CC=C3)C3=CC2)c1)=N 0.000 description 3
- AWHSQBQAQBXRMH-UHFFFAOYSA-N C(c(cc1)ccc1-c1nnn[nH]1)Oc1cccc(OCc2nc3ccccc3cc2)c1 Chemical compound C(c(cc1)ccc1-c1nnn[nH]1)Oc1cccc(OCc2nc3ccccc3cc2)c1 AWHSQBQAQBXRMH-UHFFFAOYSA-N 0.000 description 1
- KSLJQZMWPJNKKP-UHFFFAOYSA-O C(c(cc1)ccc1OCc1nc2ccccc2cc1)Oc(cc1)ccc1-c1n[nH+]n[nH]1 Chemical compound C(c(cc1)ccc1OCc1nc2ccccc2cc1)Oc(cc1)ccc1-c1n[nH+]n[nH]1 KSLJQZMWPJNKKP-UHFFFAOYSA-O 0.000 description 1
- KOXHPVHOZNZZSJ-UHFFFAOYSA-N C(c1cc(OCc2nc3ccccc3cc2)ccc1)Oc1cccc(-c2nnn[nH]2)c1 Chemical compound C(c1cc(OCc2nc3ccccc3cc2)ccc1)Oc1cccc(-c2nnn[nH]2)c1 KOXHPVHOZNZZSJ-UHFFFAOYSA-N 0.000 description 1
- WLGCQGMQMAOULL-UHFFFAOYSA-N C(c1cccc(-c2nnn[nH]2)c1)Oc1cc(OCc2nc3ccccc3cc2)ccc1 Chemical compound C(c1cccc(-c2nnn[nH]2)c1)Oc1cc(OCc2nc3ccccc3cc2)ccc1 WLGCQGMQMAOULL-UHFFFAOYSA-N 0.000 description 1
- LRHAGGWPAYKDOL-UHFFFAOYSA-N C(c1nnn[nH]1)Oc1ccc(COc2cccc(OCc3nc4ccccc4cc3)c2)cc1 Chemical compound C(c1nnn[nH]1)Oc1ccc(COc2cccc(OCc3nc4ccccc4cc3)c2)cc1 LRHAGGWPAYKDOL-UHFFFAOYSA-N 0.000 description 1
- SSPUCOWJOYUIGO-UHFFFAOYSA-N COC(c1ccc(COc2cccc(OCc3nc4ccccc4cc3)c2)c(OCc2nnn[nH]2)c1)=O Chemical compound COC(c1ccc(COc2cccc(OCc3nc4ccccc4cc3)c2)c(OCc2nnn[nH]2)c1)=O SSPUCOWJOYUIGO-UHFFFAOYSA-N 0.000 description 1
- PTSDFSPWBZHXMQ-UHFFFAOYSA-N OC(COc(c(COc1cc(OCc2nc3ccccc3cc2)ccc1)ccc1)c1Cl)=O Chemical compound OC(COc(c(COc1cc(OCc2nc3ccccc3cc2)ccc1)ccc1)c1Cl)=O PTSDFSPWBZHXMQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6231897P | 1997-10-17 | 1997-10-17 | |
| US6590297P | 1997-11-17 | 1997-11-17 | |
| PCT/US1998/021947 WO1999020275A1 (en) | 1997-10-17 | 1998-10-16 | Therapeutic uses of quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG104432A true BG104432A (bg) | 2000-12-29 |
Family
ID=26742119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG104432A BG104432A (bg) | 1997-10-17 | 2000-05-15 | Терапевтично използване на хинолинови производни |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6376512B1 (zh) |
| EP (1) | EP1030665A4 (zh) |
| JP (1) | JP2001520193A (zh) |
| KR (1) | KR20010024533A (zh) |
| CN (1) | CN1302206A (zh) |
| AP (1) | AP2000001786A0 (zh) |
| AU (1) | AU9696198A (zh) |
| BG (1) | BG104432A (zh) |
| BR (1) | BR9814087A (zh) |
| CA (1) | CA2306825A1 (zh) |
| EA (1) | EA200000427A1 (zh) |
| HU (1) | HUP0101022A1 (zh) |
| IL (1) | IL135673A0 (zh) |
| NO (2) | NO20001962L (zh) |
| OA (1) | OA11371A (zh) |
| PL (1) | PL344977A1 (zh) |
| WO (1) | WO1999020275A1 (zh) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1177187B1 (en) | 1999-04-28 | 2007-07-25 | Sanofi-Aventis Deutschland GmbH | Di-aryl acid derivatives as ppar receptor ligands |
| JP2002543065A (ja) * | 1999-04-28 | 2002-12-17 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｐｐａｐ受容体リガンドとしてのトリアリール酸誘導体 |
| US7041691B1 (en) * | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| JP2003508389A (ja) | 1999-08-27 | 2003-03-04 | エリ リリー アンド カンパニー | ビアリール−オキサ（チア）ゾール誘導体およびそのｐｐａｒモジュレーターとしての使用 |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| TWI302149B (en) | 1999-09-22 | 2008-10-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
| TWI262185B (en) * | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| US6586438B2 (en) * | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
| JP2001261654A (ja) * | 2000-03-21 | 2001-09-26 | Mitsui Chemicals Inc | キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
| US6653332B2 (en) * | 2000-05-03 | 2003-11-25 | Tularik Inc. | Combination therapeutic compositions and method of use |
| US20030171399A1 (en) * | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| US7238716B2 (en) | 2000-12-28 | 2007-07-03 | Takeda Pharmaceuticals Company Limited | Alkanoic acid derivatives process for their production and use thereof |
| EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
| TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| HU230352B1 (hu) | 2001-06-12 | 2016-02-29 | Wellstat Therapeutics Corporation | Metabolikus rendellenességek kezelésére adható vegyületek és ezeket tartalmazó gyógyászati készítmények |
| US7371777B2 (en) | 2001-08-17 | 2008-05-13 | Eisai Co., Ltd. | Cyclic compound and PPAR agonist |
| ATE386013T1 (de) | 2002-06-20 | 2008-03-15 | Astrazeneca Ab | Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz |
| SE0201937D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
| PL374860A1 (en) | 2002-07-09 | 2005-11-14 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| EP1664002A1 (en) | 2003-09-17 | 2006-06-07 | Novartis AG | Organic compounds |
| ATE486055T1 (de) | 2004-05-05 | 2010-11-15 | High Point Pharmaceuticals Llc | Neue verbindungen, ihre herstellung und verwendung |
| JP4981662B2 (ja) | 2004-05-05 | 2012-07-25 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | 新規の化合物、その製法と使用 |
| CN100418532C (zh) * | 2005-06-17 | 2008-09-17 | 吕志民 | 治疗多种疾病的NF-κB化合物抑制剂 |
| RU2412935C2 (ru) | 2005-06-30 | 2011-02-27 | Хай Пойнт Фармасьютикалс, ЛЛС | Феноксиуксусные кислоты в качестве активаторов дельта рецепторов ppar |
| AU2006287521A1 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | PPARactive compounds |
| EP2386540A1 (en) | 2005-12-22 | 2011-11-16 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
| WO2007101864A2 (en) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Compounds that modulate ppar activity, their preparation and use |
| US9308198B2 (en) | 2006-09-08 | 2016-04-12 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced brain disease |
| US7645616B2 (en) * | 2006-10-20 | 2010-01-12 | The University Of Hong Kong | Use of lipocalin-2 as a diagnostic marker and therapeutic target |
| RU2522458C2 (ru) * | 2008-04-30 | 2014-07-10 | Веллстат Терапьютикс Корпорейшн | Тетразольные соединения для снижения концентрации мочевой кислоты |
| BRPI1011318A2 (pt) | 2009-06-09 | 2019-09-24 | California Capital Equity Llc | derivados de triazina e suas aplicações terapêuticas |
| CA2765044A1 (en) | 2009-06-09 | 2010-12-16 | California Capital Equity, Llc | Benzyl substituted triazine derivatives and their therapeutical applications |
| WO2010144586A1 (en) | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling |
| ES2533065T3 (es) | 2010-07-09 | 2015-04-07 | Pfizer Limited | Bencenosulfonamidas útiles como inhibidores de los canales de sodio |
| CA2801032A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
| JP2013531030A (ja) | 2010-07-12 | 2013-08-01 | ファイザー・リミテッド | 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド |
| CA2804716A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| CA2804877A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
| US8772343B2 (en) | 2010-07-12 | 2014-07-08 | Pfizer Limited | Chemical compounds |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US10099993B2 (en) * | 2014-04-06 | 2018-10-16 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof |
| CN116323560A (zh) * | 2020-08-04 | 2023-06-23 | 精密生物治疗有限责任公司 | 作为胆汁酸受体和白三烯半胱氨酰受体的选择性和/或双重调节剂的喹啉化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| US4920132A (en) * | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US4920130A (en) * | 1987-11-02 | 1990-04-24 | Rorer Pharamceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| ATE177083T1 (de) * | 1993-11-29 | 1999-03-15 | Merrell Pharma Inc | Benzolsulfonyliminderivate als inhibitoren der il-1 wirkung |
| EP0709377B1 (en) * | 1994-10-27 | 1999-09-29 | Asahi Glass Company Ltd. | Process for producing quinolin-2-yl benzoic acid compounds |
| DK0871439T3 (da) * | 1996-01-02 | 2004-08-02 | Aventis Pharma Inc | Substituerede (aryl, heteroaryl, arylmethyl eller heteroarylmethyl) hydroxamsyreforbindelser |
-
1998
- 1998-10-16 EP EP98951075A patent/EP1030665A4/en not_active Withdrawn
- 1998-10-16 JP JP2000516672A patent/JP2001520193A/ja active Pending
- 1998-10-16 WO PCT/US1998/021947 patent/WO1999020275A1/en not_active Application Discontinuation
- 1998-10-16 CA CA002306825A patent/CA2306825A1/en not_active Abandoned
- 1998-10-16 IL IL13567398A patent/IL135673A0/xx unknown
- 1998-10-16 KR KR1020007004131A patent/KR20010024533A/ko not_active Application Discontinuation
- 1998-10-16 CN CN98811303A patent/CN1302206A/zh active Pending
- 1998-10-16 AU AU96961/98A patent/AU9696198A/en not_active Abandoned
- 1998-10-16 PL PL98344977A patent/PL344977A1/xx unknown
- 1998-10-16 EA EA200000427A patent/EA200000427A1/ru unknown
- 1998-10-16 BR BR9814087-6A patent/BR9814087A/pt not_active Application Discontinuation
- 1998-10-16 HU HU0101022A patent/HUP0101022A1/hu unknown
-
2000
- 2000-01-27 US US09/490,897 patent/US6376512B1/en not_active Expired - Fee Related
- 2000-04-07 AP APAP/P/2000/001786A patent/AP2000001786A0/en unknown
- 2000-04-13 OA OA1200000106A patent/OA11371A/en unknown
- 2000-04-14 NO NO20001962A patent/NO20001962L/no not_active Application Discontinuation
- 2000-05-15 BG BG104432A patent/BG104432A/bg unknown
- 2000-06-16 NO NO20003107A patent/NO20003107L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2306825A1 (en) | 1999-04-29 |
| NO20003107D0 (no) | 2000-06-16 |
| US6376512B1 (en) | 2002-04-23 |
| IL135673A0 (en) | 2001-05-20 |
| EP1030665A1 (en) | 2000-08-30 |
| AP2000001786A0 (en) | 2000-04-16 |
| PL344977A1 (en) | 2001-11-19 |
| EA200000427A1 (ru) | 2001-02-26 |
| AU9696198A (en) | 1999-05-10 |
| OA11371A (en) | 2004-01-28 |
| KR20010024533A (ko) | 2001-03-26 |
| NO20001962L (no) | 2000-06-16 |
| NO20003107L (no) | 2000-07-26 |
| EP1030665A4 (en) | 2002-11-27 |
| JP2001520193A (ja) | 2001-10-30 |
| WO1999020275A1 (en) | 1999-04-29 |
| BR9814087A (pt) | 2000-10-03 |
| NO20001962D0 (no) | 2000-04-14 |
| HUP0101022A1 (hu) | 2001-10-28 |
| CN1302206A (zh) | 2001-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG104432A (bg) | Терапевтично използване на хинолинови производни | |
| US20030220373A1 (en) | Therapeutic uses of PPAR mediators | |
| TW584560B (en) | Pharmaceutical composition of substituted indolealkanoic acids for reducing serum glucose and triglyceride levels and inhibiting angiogenesis | |
| KR100709498B1 (ko) | Ｐｐａｒ 수용체 리간드로서의 디아릴 산 유도체 | |
| JP2003525217A (ja) | 肥満治療用薬剤 | |
| CN101268060A (zh) | 噻唑啉酮和噁唑啉酮类化合物及其作为ptp1b抑制剂的应用 | |
| US20210047337A1 (en) | Triazolopyrimidines, their preparation and use | |
| TW200803896A (en) | Method of improvement of cognitive function | |
| BRPI0615046B1 (pt) | uso de um composto | |
| CN101948416A (zh) | 用于治疗代谢紊乱的化合物 | |
| EP1572180B1 (en) | Use of alpha-phenylthiocarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity | |
| WO2004093910A1 (ja) | ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤 | |
| US10377695B2 (en) | Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof | |
| AU2007257854B2 (en) | Compounds for the treatment of metabolic disorders | |
| JP2000500490A (ja) | 糖尿病治療用の４−ヒドロキシクマリン−３−カルボキシアミド | |
| TW201818964A (zh) | 使用色胺酸羥化酶抑制劑之方法 | |
| WO2021032218A1 (zh) | 一种并环THRβ受体激动剂化合物及其制备方法和用途 | |
| CN108299411B (zh) | 4,4-二苯基哌啶类化合物或其可药用盐、药物组合物及用途 | |
| ZA200506257B (en) | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | |
| JPH09505081A (ja) | ５−リポキシゲナーゼ阻害物質としてのイソキサゾリン化合物 |